Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vardenafil treatment for erectile dysfunction.

Susan M Crowe1, Daniel S Streetman

  • 1Department of Pharmacy Services, University of Michigan Health System, University of Michigan, Ann Arbor, MI, USA.

The Annals of Pharmacotherapy
|January 27, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Optimization of Antibiotic Prophylaxis Delivery for Pediatric Surgical Procedures.

Pediatrics·2021
Same author

Interpretation of Cytochrome P-450 Inhibition and Induction Effects From Clinical Data: Current Standards and Recommendations for Implementation.

Clinical pharmacology and therapeutics·2020
Same author

Is there a clinically relevant interaction between clarithromycin and statins not metabolized by cytochrome P450 3A4?

CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne·2015
Same author

The use of high resolution computerized tomography (HRCT) of the chest in evaluating the effect of tobramycin solution for inhalation in cystic fibrosis lung disease.

Pediatric pulmonology·2010
Same author

Identifying barriers to treatment adherence and related attitudinal patterns in adolescents with cystic fibrosis.

Pediatric pulmonology·2010
Same author

Emergence and evolution of pharmacogenetics and pharmacogenomics in clinical pharmacy over the past 40 years.

The Annals of pharmacotherapy·2007
Same journal

Association Between Prior PARP Inhibitor Maintenance Therapy and Myelosuppression During Subsequent Chemotherapy in Ovarian Cancer.

The Annals of pharmacotherapy·2026
Same journal

Prolonged Response to Nivolumab in Metastatic Vulvar Carcinoma: Should Immunotherapy be Continued and for How Long? A Debatable Issue!

The Annals of pharmacotherapy·2026
Same journal

Stability of Ceftazidime-Avibactam: Changes in Regulatory Information and Implications for Preparation.

The Annals of pharmacotherapy·2026
Same journal

Impact of Early Dose Adjustment of Piperacillin/Tazobactam on Mortality in Critically Ill Patients With Acute Kidney Injury: A Retrospective Multicenter Cohort Study.

The Annals of pharmacotherapy·2026
Same journal

Severe Phototoxic Skin Reaction Associated With Vandetanib: Implications for Pharmaceutical Care.

The Annals of pharmacotherapy·2026
Same journal

Efficacy and Safety of Oral PCSK9 Inhibitors in Adults With Hypercholesterolemia: An Updated Systematic Review and Meta-Analysis of RCTs.

The Annals of pharmacotherapy·2026
See all related articles

Vardenafil effectively treats erectile dysfunction (ED) by inhibiting phosphodiesterase 5 (PDE5). This oral medication is safe, with mild, dose-dependent side effects and potentially fewer vision issues than sildenafil.

Area of Science:

  • Pharmacology and Therapeutics
  • Urology
  • Clinical Medicine

Background:

  • Erectile dysfunction (ED) is a common condition affecting men's sexual health.
  • Phosphodiesterase 5 (PDE5) inhibitors are a primary treatment modality for ED.
  • Understanding the efficacy and safety profiles of available PDE5 inhibitors is crucial for clinical practice.

Purpose of the Study:

  • To comprehensively review vardenafil's pharmacology, pharmacokinetics, clinical efficacy, and safety.
  • To evaluate vardenafil's role in treating erectile dysfunction across diverse patient populations.
  • To compare vardenafil's adverse effect profile with other PDE5 inhibitors, specifically sildenafil.

Main Methods:

  • Literature searches were conducted using MEDLINE and other sources up to December 2002.

Related Experiment Videos

  • Information was gathered from published human studies, manufacturer data, and professional meeting proceedings.
  • Pharmacology, pharmacokinetics, drug interactions, efficacy, and safety data were extracted from relevant studies.

    • Main Results:

    • Vardenafil is a potent and selective PDE5 inhibitor that improves erectile function in men with ED.
    • It exhibits rapid onset, hepatic metabolism, and a 4-6 hour half-life.
    • Clinical trials demonstrated efficacy in healthy men, those with diabetes, and post-prostatectomy patients, with mild, dose-dependent adverse effects (22-61% incidence).

    Conclusions:

    • Vardenafil is a safe and effective oral treatment for ED.
    • Its enhanced PDE5 selectivity may reduce vision-related side effects compared to sildenafil.
    • Further research is needed to clarify other clinical implications of its pharmacological profile.